ORIGINAL RESEARCH article
Front. Neurol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1560483
Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy
Provisionally accepted
- Fujian Medical University Union Hospital, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.All three patients exhibited proximal muscle weakness and markedly increased creatinine kinase (CK) levels. Moreover, the myositis antibody profile revealed positive anti-signal recognition particle (SRP) antibodies in all of them.Muscle biopsy performed on the first patient confirmed IMNM. Eventually, all three patients were diagnosed with anti-SRP IMNM. The first patient initially received methylprednisolone via intravenous injection and then commenced efgartigimod therapy. The second and third patients were treated with a combination of methylprednisolone intravenous injection and efgartigimod. The efficacy of efgartigimod treatment was evaluated by observing the changes in CK values and the manual muscle testing (MMT) score. Safety assessments included adverse events and serious adverse events.Results: Following one cycle of efgartigimod treatment (administered at a dosage of 10 mg/kg, once a week for a total of 4 injections in one period) in these three patients, CK values decreased by 79.30%, 95.80%, and 93.62%, respectively. Their MMT score increased from 232, 156, and 169 to 242, 258, and 229, respectively. Evidently, these three patients demonstrated significant improvement in muscle strength and decrease of serum CK levels after efgartigimod treatment. No serious adverse events were observed during the efgartigimod treatment.Discussion: Early application of efgartigimod in combination with methylprednisolone for the treatment of anti-SRP-IMNM led to a substantial decrease in CK values and effectively improved muscle strength. Consequently, Efgartigimod may may prove to be an effective and safe therapeutic option for IMNM.
Keywords: anti-SRP, IMNM, efgartigimod, FcRn inhibitor anti-SRP, FcRn inhibitor
Received: 14 Jan 2025; Accepted: 05 May 2025.
Copyright: © 2025 Peng, Yao, Chen, Li, Lin and Zou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhangyu Zou, Fujian Medical University Union Hospital, Fuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.